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TO THE EDITOR
Contact hypersensitivity (CHS) is a form
of a delayed type of hypersensitivity, a
classic T-cell-mediated, clinically im-
portant phenomenon elicited by small
molecular weight molecules (haptens)
that bind to host proteins to form
a complete allergen (Grabbe and
Schwarz, 1998). The CHS reaction can
be divided in to two phases: sensitiza-
tion and elicitation. The elicitation
phase is dominated by the production
of proinflammatory cytokines and cel-
lular infiltration by lymphocytes and
granulocytes. Infiltration is accompa-
nied by strong oxidative stress due to
the formation of superoxide, nitric
oxide, peroxynitrite, and further reac-
tive species (Rowe et al., 1997; Ross
et al., 1998).
The poly(ADP-ribose) polymerase
(PARP) superfamily consists of 17
members (Ame et al., 2004). A sub-
group of these enzymes can be acti-
vated by DNA single-strand breaks and
aberrant DNA forms (Ame et al., 1999;
Schreiber et al., 2006). In tissues and
cells, PARP-1 is responsible for most of
the PARP activity due to its abundance
and high catalytic activity. Activated
PARP-1 uses NADþ as a substrate and
synthesizes the formation of poly(ADP-
ribose) polymers covalently attached to
different acceptor proteins. The pre-
sence of poly(ADP-ribose) polymers
may regulate the functions of the
acceptor proteins (Schreiber et al.,
2006). Inhibition of PARP activity or
knocking out the PARP-1 gene has
been shown to suppress inflammatory
reactions such as colitis, arthritis, and
uveitis (Shall and De Murcia, 2000;
Virag and Szabo, 2002; Cuzzocrea,
2005). Prevention of cellular dysfunc-
tion and inhibition of NF-kB activation
have been proposed to be the mechan-
isms underlying the anti-inflammatory
effects of PARP inhibition/knockout
(Virag and Szabo, 2002).
Poly(ADP-ribose) polymerase plays
a role in the regulation of the transcrip-
tion of various inflammatory mediators
such as cytokines, chemokines, induci-
ble nitric oxide synthase, and matrix
metalloproteinases (MMPs).
In our previous report, we have
demonstrated peroxynitrite production,
DNA breakage, and poly(ADP-ribose)
formation during the elicitation phase
of the CHS (Szabo et al., 2001). More-
over, we have shown that peroxynitrite,
superoxide, and hydrogen peroxide
impair proliferation and viability of
HaCaT keratinocytes (Szabo et al.,
2001). PARP inhibitors prevented
necrotic cell death with a slight in-
crease in apoptotic DNA fragmentation
and also reduced cytokine-induced ex-
pression of IL-8 and ICAM-1 in HaCaT
cells. (Szabo et al., 2001). Kehe et al.
(2008) reported similar findings in a
model of sulfur mustard-induced cell
death of HaCaT cells. They also found
Abbreviations: CHS, contact hypersensitivity; MMP, matrix metalloproteinase; MPO, myeloperoxidase;
PARP, poly(ADP-ribose) polymerase; ROI, reactive oxygen intermediate; RNI, reactive nitrogen
intermediate; TIMP, tissue inhibitor of metalloproteinases
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that the PARP inhibitor 3-aminobenza-
mide diverted the vesicant-induced
necrotic cell death toward apoptosis.
The aim of this study was to inves-
tigate (1) whether PARP activation
contributes to CHS and (2) whether
the role of PARP in CHS is related to
regulation of chemokine expression
and MMP activation.
In our current experiment, we have
investigated the effect of the PARP
inhibitor PJ34 in the mouse model of
oxazolone-induced CHS as described
earlier (Szabo et al., 2001). Similar to
the majority of PARP inhibitors, PJ34
(see structural formula on Figure 1)
inhibits the enzyme as an NADþ
analog (Jagtap et al., 2002; Jagtap and
Szabo, 2005). PJ34 has been shown to
exert potent cytoprotective and anti-
inflammatory effects in various
cell-based and animal studies (Virag
and Szabo, 2002; Jagtap and Szabo,
2005).
Animal experiments conform with
the ‘‘Guide for the Care and Use of
Laboratory Animals’’ published by the
US National Institute of Health, and
the treatment protocol was approved by
the institutional Ethical Committee.
Thirty female CD1 mice were rando-
mized into three groups (control, CHS,
CHSþ PJ34) and were sensitized by
smearing 100ml of 2% (w/v) oxazolone
onto the preshaved abdominal wall.
Oxazolone was dissolved in aceto-
ne:olive oil 1:4 mixture. (The control
group was mock-sensitized with the
vehicle.) One week after sensitization,
mice were treated with i.p. injection
of phosphate-buffered saline (control
group and CHS group) or with PJ34
(10 mg kg1) before the application of
410 ml 0.5% (w/v) oxazolone onto
the inner and outer surface of the ear on
both sides. After 24 hours, thickness of
ears was measured and tissue samples
are taken for laboratory investigations.
Oxazolone challenge of presensitized
animals resulted in the swelling of the
ears (Figure 2a and b). PARP inhibition
by PJ34 prevented edema (Figure 2a
and b), indicating a lower level of
inflammation. We have determined
cellular infiltration by enzyme histo-
chemistry detecting peroxidase activity
(Figure 2a). For the peroxidase staini-
ng, see Supplementary Method 1. The
increase in the myeloperoxidase (MPO)
activity (determined as described by
Virag et al., 2004) upon inflammation
suggested the presence of granulocytes
in the infiltrate. PARP inhibition by
PJ34 decreased the number of infiltrat-
ing cells as shown by peroxidase
staining and by determining the MPO
O
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Figure 1. Structure of PJ34.
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Figure 2. Inhibition of neutrophil infiltration by PJ34. (a) CHS reaction was induced in oxazolone-
sensitized mice by smearing oxazolone on both sides of the ears (n¼ 10). Sections of ears were stained
with hematoxylin and eosin, and enzyme histochemistry was used to detect peroxidase activity.
Oxazolone-induced CHS resulted in edema in the dermis, which could be suppressed by PJ34 treatment.
PJ34 treatment reduced the number of peroxidase-positive cells in the ears (n¼ 10). (Bar¼ 1,000 mm for
the images of hematoxylin-and-eosin staining and 400 mm for the images of peroxidase staining).
(b) Measurement of ear thickness provided further support for the involvement of PARP in CHS-induced
inflammation. Ears of mice in the CHS group (n¼ 10) were markedly thicker due to edema formation.
PJ34 significantly reduced edema (n¼ 10; ***Po0.001, #Po0.05). (c) In line with the peroxidase
staining, myeloperoxidase activity of ear lysates also indicated granulocyte infiltration in the CHS group
(n¼10). MPO activity was efficiently reduced by PJ34 pretreatment. (n¼ 10, ***Po0.001, #Po0.05).
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activity of ear lysates (Figure 2a and c).
Epicutaneously applied haptens may
also induce nonantigen-specific irritant
dermatitis (Grabbe et al., 1996). To see
whether PARP inhibition also suppresses
irritant dermatitis, we have determined
the effect of PJ34 on 12-O-tetrade-
canoyl-phorbol 13-acetate-induced ear
swelling. 12-O-tetradecanoyl-phorbol
13-acetate (10ml, 0.05% w/v) was
smeared onto both sides of the ears
of female mice (n¼ 8 animals per
group) immediately followed by PJ34
or vehicle treatment as described above.
12-O-tetradecanoyl-phorbol 13-acetate
induced a less severe inflammation
as compared with oxazolone, and the
PARP inhibitor significantly reduced ear
swelling and inhibited cellular infiltra-
tion (MPO activity) (Figure S1), indicat-
ing that it targets general inflammatory
pathways rather than specific immune
response.
Poly(ADP-ribose) polymerase-1 has
been shown earlier to regulate the
expression of chemokines in various
models of inflammation (Virag and
Szabo, 2002). Macrophage inflammatory
protein-1a, one of the main chemo-
attractant of neutrophil granulocytes,
and other proinflammatory chemo-
kines/cytokines such as macrophage
inflammatory protein-2, tumor necrosis
factor-a, and IL-1b were induced in
the allergic reaction and was reduced
by PJ34 (Figure 3a). Levels of these
cytokines were determined with com-
mercially available (R&D System,
Minneapolis, MN) ELISA assay kits.
We also set out to investigate
whether PARP activity regulates MMP
expression in CHS. MMPs are secreted
by a variety of skin-resident and
infiltrating cells, including fibroblasts,
endothelial cells, macrophages, neutro-
phils, and lymphocytes. These enzymes
are expressed as zymogens, which are
subsequently processed either by other
proteolytic enzymes or by free radicals
triggering structural changes resulting in
full-length active MMPs (Pacher et al.,
2003; Le et al., 2007). The MMP activity
is counterbalanced by a family of tissue
inhibitors, called tissue inhibitors of
metalloproteinases (TIMPs). Metallo-
proteinase activity of ear extracts was
determined by gelatin zymography as
described by Pacher et al. (2002). In
CHS samples, a band with an apparent
molecular weight of 89–92 kDa was
found to be upregulated. PJ34 treatment
suppressed this activity (Figure 3b). The
molecular weight (89–92 kDa) sug-
gested that MMP-9 expression can be
responsible for the appearance of this
band. By western blotting, we have
detected an increase in the level of
MMP-9 upon inflammation and PJ34
reversed MMP expression (Figure 3b).
Moreover, we have detected a decrea-
sed expression of TIMP-2 in CHS
samples, which was prevented by PJ34
pretreatment (Figure 3b).
Hereby, we provide evidence for the
involvement of PARP in the pathome-
chanism of inflammation in CHS. PARP
inhibition reduced edema (ear swelling)
and the migration of inflammatory cells
to the site of inflammation. Reactive
oxygen and nitrogen intermediates (ROI
and RNI, respectively) are produced in
large quantity in inflammatory condi-
tions including CHS and constitute
important pathogenetic factors trigger-
ing endothelial dysfunction (Virag
et al., 2002). ROI and RNI can stimulate
the DNA breakage–PARP-1 activation
pathway that has been shown to medi-
ate endothelial dysfunction in other
experimental settings such as in dia-
betic blood vessels (Soriano et al.,
2001; Pacher and Szabo, 2005). We
hypothesize that similar mechanisms
may underlie the anti-inflammatory
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Figure 3. Cytokine expression and MMP activation in CHS. (a) Cytokines (tumor necrosis factor-a, IL-1b)
and chemokines (macrophage inflammatory protein-1a, macrophage inflammatory protein-2) were
determined from ear lysates by using commercially available (R&D System) ELISA kits. All cytokines and
chemokines investigated were upregulated in the CHS samples (n¼10) as compared with control
(n¼10). PJ34 inhibited the expression of all four cytokines/chemokines. (n¼ 10; *Po0.05, ***Po0.001,
#Po0.05). (b) Expression and activation of MMPs have been studied by zymography and western blot,
respectively. A 89–92 kDa proteinase activity is detected in the inflamed ears, whereas its activity was
abrogated upon pretreatment with PJ34. Western blotting with an MMP-9 antibody verified that there is a
mild increase in the expression of MMP-9, suggesting MMP-9 to be implicated in the inflammatory
process. TIMP-2 protein level decreased in CHS samples, and this decreased TIMP-2 expression was
prevented by PJ34 treatment (n¼ 6 in each group). Minor adjustment to contrast has been made on the
western blot images.
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effects of PARP inhibition in CHS (see
Figure S2). Various skin-resident cell
types and immigrating inflammatory cells
can produce ROI and RNI (Trouba et al.,
2002; Virag et al., 2002; Okayama,
2005). Oxidative stress may cause DNA
breakage and activate PARP-1 in endo-
thelial cells, which may cause endo-
thelial dysfunction through depletion
of NADþ and ATP. PARP inhibitors
may interfere with this pathway at
two points. They may directly prevent
the depletion of energy metabolites and
may reduce the amount of ROI/RNI
produced during inflammation. As most
ROI/RNI are likely produced by the
infiltrating granulocytes, inhibition of
granulocyte migration from the circula-
tion to the site of inflammation may
result in suppressed ROI/RNI produc-
tion. Indeed, our results indicate that
PARP inhibition markedly inhibits the
extravasation of granulocytes as indi-
cated by peroxidase staining and MPO
activity measurements of ear lysates.
Extravasation of leukocytes is mediated
by the expression of different adhesion
molecules on the surface of the leuko-
cytes and the endothelium. PARPs have
been shown to regulate the expression
of adhesion molecules, such as ICAM-1
in various cell types including endo-
thelial cells and cytokine-stimulated
HaCaT keratinocytes (Zingarelli et al.,
1998; Szabo et al., 2001). Therefore, it
is likely that in vivo inhibition of PARP
activity may regulate the adhesion of
the infiltrating cells to the vascular
endothelium and thus influences
the severity of inflammation in CHS.
The other mechanism that may explain
the inhibitory effect of PARP inhibition
on the migration of inflammatory cells
is the reduced expression of inflamma-
tory cytokines (for example, tumor
necrosis factor-a and IL-1b), with special
regard to chemokines, the chemotactic
cytokines. PARP-1 has been shown
to act as a coactivator of NF-kB, a trans-
cription factor involved in the expres-
sion of inflammatory mediators. This
effect may explain the suppressing
effect of the PARP inhibitor on the
production of chemokines and cytokines
in CHS.
Matrix metalloproteinases are now
considered as inflammatory mediators
as indicated by the anti-inflammatory
effects of MMP inhibitors as demon-
strated in various models of inflamma-
tion including CHS (Hu et al., 2007).
Active MMPs facilitate the movement
of the infiltrating immune cells through
the protein mesh of the extracellular
matrix. MMP-9 expression is inducible
in many cell types by proinflammatory
cytokines such as tumor necrosis factor-
a or IL-1b (Doller et al., 2007; Li et al.,
2007), and MMP-9 can be also be
synthesized by a number of cell types
in the inflamed skin, such as keratino-
cytes (Lamar et al. 2008), granulocytes
(Matsuzaki et al., 2006), or dendritic
cells (Zozulya et al., 2007). As MMP
expression is under the control of
NF-kB (Bond et al., 1998), inhibition
of MMP-9 expression by PJ34 may
be explained by the same mechanism
as outlined above for inflammatory
cytokines and chemokines. Moreover,
the decrease of TIMP-2 may also lead to
the activation of MMPs.
In summary, our data demonstrate
that PARP activity mediates inflamma-
tion in CHS. PARP acts as a pleiotropic
modulator of the inflammatory reaction
by enhancing leukocyte migration,
production of inflammatory cytokines
and chemokines, and the activation
of MMPs. Whether or not local
PARP inhibition is a viable therapeutic
approach in human CHS-like condi-
tions requires further investigation, with
special regard to a potential sensitizing
effect of PARP inhibitors to carcino-
genic stimuli.
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Supplementary Materials and Methods. Cyto-
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Figure S1. PJ34 inhibits 12-O-tetradecanoyl-
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9p21 Deletion in Primary Cutaneous Large B-Cell
Lymphoma, Leg Type, May Escape Detection by Standard
FISH Assays
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TO THE EDITOR
Primary cutaneous large B-cell lympho-
ma, leg type is a neoplastic proliferation
of large, atypical B-lymphocytes, typi-
cally presenting with rapidly growing,
reddish-brown plaques and tumors on
the lower legs (Cerroni et al., 2005;
Willemze et al., 2005). The 5-year
survival rate is around 50% (Willemze
et al., 2005). The main adverse prog-
nostic factors include advanced age,
presence of multiple skin lesions, and
location on the leg (Kodama et al., 2005;
Grange et al., 2007). Recently, deletion
at chromosome region 9p21 has been
associated with a poor prognosis, pre-
dicting a 5-year survival rate of 27% as
compared to 100% in cases without
deletion (Senff et al., 2007). Among
different techniques for the identification
of the 9p21 deletion, such as multiplex
ligation-dependent probe amplification
or array-based comparative genomic
hybridization (CGH), interphase fluores-
cence in situ hybridization (FISH) em-
ploying commercially available probes
(Vysis) has evolved as standard method
(Wiesner et al., 2005; Dijkman et al.,
2006; Senff et al., 2007). The assessment
of clinical, histopathological, and mole-
cular genetic features in each patient
with primary cutaneous large B-cell
lymphoma, leg type, is crucial for
individualized management decisions,
which may range from local radiotherapy
to aggressive systemic chemotherapy.
Here we show that determination of
9p21 deletions may require more sophis-
ticated approaches than the aforemen-
Abbreviations: BAC, bacterial artificial chromosome; CGH, comparative genomic hybridization;
FISH, fluorescence in situ hybridization
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